MOA Life Plus Co. Ltd. Logo

MOA Life Plus Co. Ltd.

Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.

142760 | KO

Overview

Corporate Details

ISIN(s):
KR7142760008
LEI:
Country:
South Korea
Address:
경기도 용인시 수지구 신수로 767 7층 (동천동, 분당수지유타워 지식산업센터), 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MOA Life Plus Co. Ltd. (formerly BioLeaders Corp.) is a biopharmaceutical and healthcare company focused on developing innovative treatments and consumer products. The company's pharmaceutical division develops biopharmaceuticals, including immunotherapies, cancer treatments, and vaccines, utilizing a proprietary platform technology based on poly-gamma-glutamic acid (γ-PGA) and probiotics to enhance immune responses. Its clinical pipeline includes candidates for conditions such as cervical cancer and muscular dystrophy. The consumer business division provides tailored, clinically researched solutions for immunity enhancement, skin rejuvenation, and pet healthcare. The company supports its innovations with an extensive portfolio of domestic and international patents.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Capital/Financing Update
[기재정정]주요사항보고서(자기전환사채매도결정)
Korean 45.4 KB
2025-08-18 00:00
Legal Proceedings Report
파생상품거래손실발생
Korean 6.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-11 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 7.6 KB
2025-07-29 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 11.8 KB
2025-07-24 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 12.2 KB
2025-07-24 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 11.2 KB
2025-07-24 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 72.5 KB
2025-07-24 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 37.3 KB
2025-07-18 00:00
Capital/Financing Update
타인에대한채무보증결정
Korean 20.0 KB
2025-07-18 00:00
Related Party Transaction
[기재정정]타인에대한채무보증결정
Korean 24.4 KB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 70.8 KB
2025-07-02 00:00
Share Issue/Capital Change
전환가액의조정
Korean 16.6 KB
2025-07-01 00:00
Share Issue/Capital Change
전환청구권행사
Korean 12.9 KB
2025-06-26 00:00
Delisting Announcement
해산사유발생(종속회사의주요경영사항)
Korean 9.2 KB

Automate Your Workflow. Get a real-time feed of all MOA Life Plus Co. Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MOA Life Plus Co. Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MOA Life Plus Co. Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.